By Jared S. Hopkins
Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, including building four new plants.
The North Chicago, Ill.-based pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the threat of tariffs looms over the industry.
Chief Executive Rob Michael told analysts Friday the company is working to mitigate the impact of any tariffs through possible supply chain actions, cost efficiencies, and expanding domestic manufacturing beyond 11 U.S. sites. AbbVie doesn't plan to pass price increases onto customers, he said.
AbbVie estimated a $30 million impact due to existing tariffs, which the company is absorbing, AbbVie said.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 25, 2025 12:02 ET (16:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.